共 50 条
- [21] Discovery of AG-120: A first-in-class inhibitor of IDH1 mutant enzymes for the treatment of cancers harboring IDH1 mutationsABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252Popovici-Muller, JanetaLemieux, ReneSaunders, JeffreySalituro, FrancescoYen, KatharineStraley, KimberlyTobin, EricaWang, FangGross, StefanArtin, ErinDang, LennyYang, HuaUtley, LukeChen, YueOlaharski, AndrewSilverman, LeeAgresta, SamSu, MichaelBiller, Scott
- [22] A phase I study of the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Pardee, Timothy S.Levitan, Denise A.Hurd, David DuaneEllis, Leslie R.Isom, ScottHarrelson, RobinManuel, MeganDralle, SarahLyerly, SusanPowell, Bayard L.
- [23] Longitudinal Pharmacokinetic/Pharmacodynamic Profile of AG-120, a Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-Mutant Advanced Hematologic MalignanciesBLOOD, 2015, 126 (23)Fan, BinLe, KhaManyak, ErikaLiu, HuaPrahl, MaliaBowden, Chris J.Biller, ScottAgresta, SamYang, Hua
- [25] First-in-Human Phase 1 Trial of VT3989, a First-in-Class YAP/TEAD Inhibitor in Patients with Advanced MesotheliomaJOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S384 - S384Yap, T.Desai, J.Dagogo-Jack, I.Millward, M.Kindler, H. L.Tolcher, A. W.Frentzas, S.Body, A. L.Thurston, A.Post, L.Dorr, F. A.Kwiatkowski, D. J.
- [26] AG-120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: UPDATED RESULTS FROM THE PHASE 1 NON-ENHANCING GLIOMA POPULATIONNEURO-ONCOLOGY, 2017, 19 : 10 - 11Mellinghoff, Ingo K.Touat, MehdiMaher, ElizabethDe la Fuente, MacarenaCloughesy, Timothy F.Holdhoff, MatthiasCote, Gregory M.Burris, HowardJanku, FilipHuang, RayYoung, Robert J.Ellingson, BenjaminNimkar, TaraJiang, LiewenIshii, YukoChoe, SungFan, BinSteelman, LoriYen, KatharineBowden, ChrisPandya, SusanWen, Patrick Y.
- [27] Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple MyelomaBLOOD, 2023, 142Berdeja, Jesus G.Dingli, DavidLonial, SagarYee, Andrew J.Chung, AlfredGasparetto, CristinaLeif Bergsagel, P.Roy, VivekAbdallah, Al-OlaThanendrarajan, SharmilanAfrough, AimazRosinol, LauraTrudel, SuzanneRodriguez Otero, PaulaTouzeau, CyrilleBories, PierreBang, SooConnolly, TerryKim, MichelleLewis, Chad A.Linberg, Bao-Van TranTravis Quigley, M.Landgren, OlaUsmani, Saad Z.Mateos, Maria-VictoriaSiegel, David S.
- [28] Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 TrialBLOOD, 2015, 126 (23)Stein, Eytan M.DiNardo, CourtneyAltman, Jessica K.Collins, RobertDeAngelo, Daniel J.Kantarjian, Hagop M.Sekeres, Mikkael A.Fathi, Amir T.Flinn, Ian W.Frankel, Arthur E.Levine, Ross L.Medeiros, Bruno C.Patel, Manish R.Pollyea, DanielRoboz, Gail J.Stone, Richard M.Swords, Ronan T.Tallman, Martin S.Yen, KatherineAttar, Eyal C.Xu, QiangTosolini, AlessandraMei, Jay M.Thakurta, AnjanKnight, Robert D.De Botton, Stephane
- [29] Trial in progress: Phase 1 dose escalation study of T-1101, a first-in-class oral Hec1/Nek2 inhibitor, in patients with advanced refractory solid tumorsCANCER RESEARCH, 2024, 84 (07)Su, Wu-ChouBai, Li-YuanHsiao, Hui-HuaShiah, Her-ShyongYeh, Yu-MinChen, Shang-HungWu, Shang-YinWang, Hui-ChingTsai, Hui-JenChang, Kwang-YuTsai, Jui-HungLee, Chun-HuiLee, Chieh HuaChao, Yu-ShengChen, Li-Tzong
- [30] A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Gabrail, Nashat Y.Hamilton, Erika P.Elias, Anthony D.Rimawi, Mothaffar F.Li, ChaoCorvez, Maria MargaritaLi, WeiFeng, YingWei, JiaoGreene, StephaniePatterson, JohnZeng, QingpingHui, Ai-Min